Form 8-K - Current report:
SEC Accession No. 0001213900-21-062812
Filing Date
2021-12-01
Accepted
2021-12-01 14:45:46
Documents
15
Period of Report
2021-12-01
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea151570-8k_180lifesci.htm   iXBRL 8-K 37790
2 PRESS RELEASE DATED DECEMBER 1, 2021 ea151570ex99-1_180lifesci.htm EX-99.1 12365
3 TRANSCRIPT OF PRESENTATION PRESENTED BY PROF. JAGDEEP NANCHAHAL, AT THE 2021 INT ea151570ex99-2_180lifesci.htm EX-99.2 29826
  Complete submission text file 0001213900-21-062812.txt   318650

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE atnf-20211201.xsd EX-101.SCH 3790
5 XBRL DEFINITION FILE atnf-20211201_def.xml EX-101.DEF 26659
6 XBRL LABEL FILE atnf-20211201_lab.xml EX-101.LAB 36698
7 XBRL PRESENTATION FILE atnf-20211201_pre.xml EX-101.PRE 25277
8 EXTRACTED XBRL INSTANCE DOCUMENT ea151570-8k_180lifesci_htm.xml XML 5688
Mailing Address 830 MENLO AVENUE, SUITE 100 MENLO PARK CA 94025
Business Address 830 MENLO AVENUE, SUITE 100 MENLO PARK CA 94025 650-507-0669
180 Life Sciences Corp. (Filer) CIK: 0001690080 (see all company filings)

EIN.: 813832378 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38105 | Film No.: 211462588
SIC: 2834 Pharmaceutical Preparations